| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | TW 37 | GDSC1000 | pan-cancer | AAC | -0.18 | 2e-06 |
| mRNA | BRD-K19103580 | CTRPv2 | pan-cancer | AAC | 0.18 | 1e-05 |
| mRNA | GSK461364 | CTRPv2 | pan-cancer | AAC | -0.15 | 2e-05 |
| mRNA | Doxorubicin | gCSI | pan-cancer | AAC | -0.29 | 4e-05 |
| mRNA | BRD-K09587429 | CTRPv2 | pan-cancer | AAC | 0.18 | 6e-05 |
| mRNA | GSK269962A | GDSC1000 | pan-cancer | AAC | -0.14 | 0.0001 |
| mRNA | BRD-K45681478 | CTRPv2 | pan-cancer | AAC | 0.15 | 0.0003 |
| mRNA | Erlotinib | CCLE | pan-cancer | AAC | 0.2 | 0.0004 |
| mRNA | PF-750 | CTRPv2 | pan-cancer | AAC | 0.14 | 0.0007 |
| mRNA | A-804598 | CTRPv2 | pan-cancer | AAC | 0.17 | 0.0009 |